3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 4
1
Phase 3
1
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Breast Neoplasms
5
Thyroid Neoplasms
1
Patient Acceptance of Health Care
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Endometrial Neoplasms
1
Carcinoma, Renal Cell
1
Interventions
Sunitinib
5
Everolimus
5
Nivolumab
4
pazopanib
3
cabozantinib
2
aldesleukin
2
palbociclib
1
olaparib
1
lenvatinib
1
Zoledronic Acid
1
Tobacco Use Cessation Devices
1
Standard of Care
1
Specimen Handling
1
Sorafenib
1
Single Person
1
Radiotherapy
1
Psychiatric Rehabilitation
1
Polymerase Chain Reaction
1
Nutrition Therapy
1
Midazolam
1
Ipilimumab
1
Interferons
1
Immune Checkpoint Inhibitors
1
High-Energy Shock Waves
1
Gene Expression Profiling
1
Gemcitabine
1
Erlotinib Hydrochloride
1
Early Intervention, Educational
1
Counseling
1
Caffeine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Carcinoma, Renal Cell
×
palbociclib
×
Clear all
NCT05949424
2023-11-29
OPTI-DOSE
University Medical Center Groningen
Phase 4
Unknown
30 enrolled